FY2025 EPS Estimates for GoodRx Holdings, Inc. (NASDAQ:GDRX) Increased by Analyst

by · The Cerbat Gem

GoodRx Holdings, Inc. (NASDAQ:GDRX – Free Report) – Equities researchers at Leerink Partnrs upped their FY2025 earnings per share (EPS) estimates for GoodRx in a research note issued to investors on Tuesday, October 1st. Leerink Partnrs analyst M. Cherny now anticipates that the company will post earnings of $0.23 per share for the year, up from their previous forecast of $0.22. The consensus estimate for GoodRx’s current full-year earnings is $0.14 per share.

A number of other analysts have also weighed in on GDRX. Raymond James upgraded GoodRx from an “outperform” rating to a “strong-buy” rating and set a $10.00 price objective for the company in a report on Friday, August 9th. Citigroup decreased their price objective on GoodRx from $11.00 to $10.00 and set a “buy” rating for the company in a report on Friday, August 9th. Royal Bank of Canada reiterated an “outperform” rating and set a $10.00 price objective on shares of GoodRx in a report on Friday, August 16th. UBS Group decreased their price objective on GoodRx from $9.00 to $8.50 and set a “neutral” rating for the company in a report on Friday, August 9th. Finally, Morgan Stanley upped their target price on GoodRx from $7.00 to $9.50 and gave the company an “equal weight” rating in a research report on Monday, June 10th. One research analyst has rated the stock with a sell rating, four have assigned a hold rating, nine have given a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, GoodRx currently has an average rating of “Moderate Buy” and an average price target of $9.36.

View Our Latest Stock Report on GDRX

GoodRx Stock Up 3.1 %

Shares of NASDAQ:GDRX opened at $7.09 on Thursday. The business’s 50 day moving average is $7.66 and its 200 day moving average is $7.57. The company has a quick ratio of 7.32, a current ratio of 7.32 and a debt-to-equity ratio of 0.96. The stock has a market cap of $2.66 billion, a P/E ratio of -709.00, a price-to-earnings-growth ratio of 3.38 and a beta of 1.37. GoodRx has a 52-week low of $4.14 and a 52-week high of $9.26.

GoodRx (NASDAQ:GDRX – Get Free Report) last released its earnings results on Thursday, August 8th. The company reported $0.08 EPS for the quarter, missing analysts’ consensus estimates of $0.09 by ($0.01). The business had revenue of $200.60 million for the quarter, compared to the consensus estimate of $200.47 million. GoodRx had a negative net margin of 7.57% and a positive return on equity of 3.63%. The company’s quarterly revenue was up 5.7% compared to the same quarter last year. During the same period in the prior year, the company posted $0.02 EPS.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in the stock. Beacon Capital Management LLC acquired a new position in GoodRx in the first quarter valued at approximately $28,000. Plato Investment Management Ltd acquired a new position in GoodRx in the second quarter valued at approximately $43,000. Dark Forest Capital Management LP acquired a new position in GoodRx in the second quarter valued at approximately $86,000. Gerber LLC acquired a new position in GoodRx in the fourth quarter valued at approximately $75,000. Finally, EntryPoint Capital LLC lifted its holdings in GoodRx by 165.2% in the first quarter. EntryPoint Capital LLC now owns 18,538 shares of the company’s stock valued at $132,000 after acquiring an additional 11,548 shares during the last quarter. 63.77% of the stock is currently owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other GoodRx news, major shareholder Equity Vii L.P. Spectrum sold 10,677 shares of the business’s stock in a transaction that occurred on Tuesday, September 3rd. The stock was sold at an average price of $7.86, for a total transaction of $83,921.22. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. 4.17% of the stock is owned by company insiders.

About GoodRx

(Get Free Report)

GoodRx Holdings, Inc, together with its subsidiaries, offers information and tools that enable consumers to compare prices and save on their prescription drug purchases in the United States. The company operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and access to negotiated prices.

Featured Stories